We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $83M invested in Lineage Cell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,400% more call options, than puts
Call options by funds: $15K | Put options by funds: $1K
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
11% more funds holding
Funds holding: 104 → 115 (+11)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0.39% more ownership
Funds ownership: 43.15% → 43.54% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $89.1M → $83M (-$6.06M)
Holders
115
Holders Change
+11
Holders Change %
+10.58%
% of All Funds
1.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
27
Reduced
25
Closed
4
Calls
$15K
Puts
$1K
Net Calls
+$14K
Net Calls Change
-$50K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$742K |
| 2 |
RA
Raffles Associates
New York
|
+$596K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$209K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$185K |
| 5 |
Barclays
London,
United Kingdom
|
+$174K |
Top Sellers
| 1 |
BlackRock
New York
|
-$829K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$770K |
| 3 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$235K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$165K |
| 5 |
Citigroup
New York
|
-$120K |
